HopeStage
Back to all studies
CompletedNCT06620042

Brain imaging during ketamine care for bipolar depression

About this title

FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression

Read the official source — NCT06620042
Medication studyAges 18–75United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 75 years.

What did participation involve?

The protocol includes: Having magnetic resonance imaging (MRI) scans.

Listed locations
Cleveland and 1 more locationSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: November 12, 2024
Recruitment status
Completed
Enrollment listed in the registry
20
Sponsor
Drew Cumming
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 75 Years
Official registry ID
NCT06620042
Official title
Show the full official title

Functional Magnetic Resonance Imaging of Patients Receiving Intravenous Ketamine for Treatment Resistant Bipolar Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Cleveland · Ohio City

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did participation involve?

The protocol called for participants to have MRI scans.

Who is behind this study?

The study sponsor is Drew Cumming.

Did this study involve medication?

Yes. The study involved medication, including ketamine.

Who was this study for?

Listed age limits: 18 years to 75 years.

Want to explore more studies?

Explore studies